Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab

Caroline T. Starling, Alison A. Messer, Anne Kleiman, Jennifer L. McQuade, Isabella C. Glitza Oliva, Carlos Antonio Torres-Cabala, Meghan Heberton

Producción científica: Articlerevisión exhaustiva

Resumen

Immune-related adverse events (irAEs) are common in patients receiving immune checkpoint inhibitors for metastatic melanoma and other advanced malignancies. Cutaneous, gastrointestinal, and endocrine (thyroid) irAEs are most prevalent, whereas neurologic irAEs are rare. We present a 73-year-old man with dementia and metastatic melanoma who developed immunotherapy-associated encephalitis and subsequently, interstitial granulomatous dermatitis with nivolumab/ipilimumab. High-dose corticosteroids successfully treated both conditions, though he never regained his baseline mental status. We review the literature on interstitial granulomatous dermatitis and encephalitis with immunotherapy.

Idioma originalEnglish (US)
Número de artículo9
PublicaciónDermatology online journal
Volumen28
N.º2
DOI
EstadoPublished - 2022

ASJC Scopus subject areas

  • Dermatology

Huella

Profundice en los temas de investigación de 'Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab'. En conjunto forman una huella única.

Citar esto